Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02011945




Registration number
NCT02011945
Ethics application status
Date submitted
21/11/2013
Date registered
16/12/2013
Date last updated
18/03/2020

Titles & IDs
Public title
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Scientific title
A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)
Secondary ID [1] 0 0
2013-002156-33
Secondary ID [2] 0 0
CA180-373
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Myeloid Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: dasatinib Only - dasatinib 100 mg QD(CP) or 140 mg QD (AP)

Experimental: Dose Level 1 - Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)

Experimental: Dose Level 2 - Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Dose Limiting Toxicities (DLT)
Timepoint [1] 0 0
Week 3 to week 6
Primary outcome [2] 0 0
Incidence of Adverse Events (AEs)
Timepoint [2] 0 0
Initiation of study drug to discontinuation of nivolumab stop date + 100 days or discontinuation of dasatinib + 30 days
Primary outcome [3] 0 0
Incidence of Serious Adverse Events (SAEs)
Timepoint [3] 0 0
Initiation of study drug to within 100 days of discontinuation of nivolumab dosing and 30 days of dasatinib dosing
Primary outcome [4] 0 0
Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology
Timepoint [4] 0 0
Up to 40 Months
Primary outcome [5] 0 0
Incidence of Abnormalities in Clinical Laboratory Tests: Liver Tests
Timepoint [5] 0 0
Up to 40 Months
Primary outcome [6] 0 0
Incidence of Laboratory Abnormalities in Specific Thyroid Tests
Timepoint [6] 0 0
Up to 40 Months
Secondary outcome [1] 0 0
Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants
Timepoint [1] 0 0
upto 36 Months
Secondary outcome [2] 0 0
Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants
Timepoint [2] 0 0
upto 36 Months
Secondary outcome [3] 0 0
Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants
Timepoint [3] 0 0
upto 36 Months
Secondary outcome [4] 0 0
Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants
Timepoint [4] 0 0
upto 36 Months
Secondary outcome [5] 0 0
Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants
Timepoint [5] 0 0
upto 36 Months
Secondary outcome [6] 0 0
Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants
Timepoint [6] 0 0
upto 36 Months
Secondary outcome [7] 0 0
Time to Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants
Timepoint [7] 0 0
Up to 36 Months
Secondary outcome [8] 0 0
Time to Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants
Timepoint [8] 0 0
Up to 36 Months
Secondary outcome [9] 0 0
Time to Major Molecular Response (MMR) - CML-AP Participants
Timepoint [9] 0 0
Up to 36 Months
Secondary outcome [10] 0 0
Duration of Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants
Timepoint [10] 0 0
Up to 36 Months
Secondary outcome [11] 0 0
Duration of Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants
Timepoint [11] 0 0
Up to 36 Months
Secondary outcome [12] 0 0
Duration of Major Molecular Response (MMR) - CML-AP Participants
Timepoint [12] 0 0
Up to 36 Months
Secondary outcome [13] 0 0
Time to Molecular Response 4.5(MR4.5) - CML-CP No Prior Dasatinib Participants
Timepoint [13] 0 0
Up to 36 Months
Secondary outcome [14] 0 0
Time to Molecular Response 4.5(MR4.5) - CML-CP Prior Dasatinib Participants
Timepoint [14] 0 0
Up to 36 Months
Secondary outcome [15] 0 0
Time to Molecular Response 4.5(MR4.5) - CML-AP Participants
Timepoint [15] 0 0
Up to 36 Months
Secondary outcome [16] 0 0
Duration of Molecular Response 4.5 (MR4.5) - CML-CP No Prior Dasatinib Participants
Timepoint [16] 0 0
Up to 36 Months
Secondary outcome [17] 0 0
Duration of Molecular Response 4.5 (MR4.5) - CML-CP Prior Dasatinib Participants
Timepoint [17] 0 0
Up to 36 Months
Secondary outcome [18] 0 0
Duration of Molecular Response 4.5 (MR4.5) - CML-AP Participants
Timepoint [18] 0 0
Up to 36 Months

Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.



* Confirmed diagnosis of Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase :

* With historically documented Ph+ cells
* =2 prior Tyrosine Kinase Inhibitors (TKI) therapies for CML
* Currently progressing, resistance to or with a suboptimal response to their most recent therapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score 0 - 1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Blast phase CML
* Known Abl-kinase mutation resistant to Dasatinib (e.g. T315I or T315A)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/02/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/12/2018
Sample size
Target
Accrual to date
Final
35
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Local Institution - St Leonards
Recruitment hospital [2] 0 0
Local Institution - Adelaide
Recruitment hospital [3] 0 0
Local Institution - Parkville
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Georgia
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Texas
Country [4] 0 0
United States of America
State/province [4] 0 0
Wisconsin
Country [5] 0 0
Canada
State/province [5] 0 0
Nova Scotia
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario
Country [7] 0 0
Canada
State/province [7] 0 0
Quebec
Country [8] 0 0
France
State/province [8] 0 0
Bordeaux
Country [9] 0 0
Germany
State/province [9] 0 0
Berlin
Country [10] 0 0
Germany
State/province [10] 0 0
Bonn
Country [11] 0 0
Germany
State/province [11] 0 0
Dresden
Country [12] 0 0
Germany
State/province [12] 0 0
Frankfurt am Main
Country [13] 0 0
Italy
State/province [13] 0 0
Napoli
Country [14] 0 0
Italy
State/province [14] 0 0
Orbassano
Country [15] 0 0
Italy
State/province [15] 0 0
Roma
Country [16] 0 0
Spain
State/province [16] 0 0
Madrid
Country [17] 0 0
Spain
State/province [17] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Trial website
https://clinicaltrials.gov/study/NCT02011945
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02011945